I'm proud of our company for bringing innovative solutions like this to market that are poised to have a meaningful impact on a real social issue as gene therapy treatment continues to show great promise. Great work being done by our One80 Health Care team!
We are pleased to announce the launch of GeneBridge, an innovative reinsurance solution created to mitigate the financial impact of high-cost gene therapy claims. Tap the link for full press release: https://bit.ly/4eHtXiQ
Innovative Life Sciences Executive | Strategic Visionary | VP Marketing, Sales, Commercial Development | Diverse Therapeutic Area Experience | Rare Disease | Board Member
Are you a life science company seeking to maximize your commercial potential? Or, possibly a clinical-stage start-up looking for a comprehensive playbook to guide your pre-launch efforts? Look no further! 🚀 Our experienced team at BW Consulting has you covered 🌟
With years of experience and a deep understanding of the Pharma and Biotech industries, our roster of professional consultants offer tailored solutions to accelerate activation and help ensure your success. From market analysis and strategic planning to product launch optimization and sales support, we've got you covered at every stage of your journey.
Let's collaborate to bring your innovations to market and drive impact in the life sciences arena. Reach out to me today to learn more about how we can elevate your commercial strategy! #LifeScience#Consulting#CommercialExcellence#Innovation#Biotech#Pharma#Healthcare#CellTherapy#GeneTherapy 🚀💼
We are excited to announce a new series: BW Bites! We will be sharing quick tangible tips for maximizing commercialization, gene therapy best practices, and more. Please check out our first piece below about getting the most out of your strategic plan.
Learn more at https://consultbw.com/ and https://bwhealthgroup.com/
#Whitepaper: As the field of Cell & Gene Therapy rapidly advances, there has been a corresponding need for supply chain solutions to meet the precise requirements of this industry.
Our newest BioServices Whitepaper discusses the growing demand for supply chain management and compliance standards needed for managing cell and gene materials. $CYRX
Read The Whitepaper: https://cyrx.co/4cFFaQ4#BioServices
Check out this article that speaks to thinking of packaging and delivery factors early and often and how that minimizes risks to the safety and efficacy of your cell and gene therapy drug product from the bench to the patient. https://bit.ly/3LrwHnN#CellandGeneTherapy
The March/April issue of Retina Specialist is out now! Inside, multiple experts cover topics such as gene therapy for nAMD, the impact of anti-VEGF biosimilars, pearls for port delivery system refills, a rundown on Eylea HD & more. Read the new issue at www.Retina-Specialist.com#retina#retinaspecialist
With over 20 years of experience manufacturing plasmid from research to GMP grade, learn how our Alderley Park and Keele centers of excellence can support your gene therapy development at whatever stage you’re in. https://okt.to/hTMo6O
For those who treat sickle cell disease, how important is the prospect of gene therapy? Our recent survey among relevant physicians highlights current perceptions around this topic. For further information, please feel free to message me or my colleague [email protected]
Head of Life Sciences BU at Savana | Catalyst in AI-Driven Digital Health & Patient-Centric Solutions for Rare Diseases | Advocating for Integrated Hemophilia Care | RWD and Insights Strategist
🔬🌐 The European Medicines Agency endorses WFH's Gene Therapy Registry!
🌟 This initiative, in collaboration with esteemed partners, is a game-changer for the Hemophilia community.
📊 The GTR's global reach is a beacon of hope, consolidating invaluable data on Hemophilia gene therapy patients worldwide. This approach not only eliminates redundancy but also promises to uncover rare safety events and elevate the overall quality of care.
💪 The primary goal of long-term safety assessment is paramount, shedding light on known and unforeseen issues. Moreover, the GTR's emphasis on efficacy and durability ensures a holistic view of Hemophilia gene therapy's impact.
🌈 It's heartening to see the commitment to patient-centric care, with programs to empower both #healthcare centers and #patients in data management. Privacy compliance is a top priority, reassuring all stakeholders.
🤝 The collaborative governance structure, complete with a Patient Advisory Group, sets a gold standard for transparent, patient-driven research.
🧬 As we embrace the future of Hemophilia care, the GTR promises to be a vital tool in shaping regulatory decisions, health technology assessments, and clinical practice #guidelines.
🚀 Looking forward to witnessing the transformative impact of the WFH GTR and its role in advancing gene therapies for Hemophilia.
#Hemophilia#GeneTherapy#PatientCare#DataForChange#HealthcareInnovationhttps://lnkd.in/ddGJHpcg
Did you miss the big news? Last week, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a pivotal letter of support, endorsing the global adoption of the WFH Gene Therapy Registry. Read the letter here! #hemophilia#genetherapyhttps://bit.ly/3Fz59cF
#Whitepaper: As the field of Cell & Gene Therapy rapidly advances, there has been a corresponding growth in supply chain solutions to meet the precise requirements of this industry.
Our newest #BioServices Whitepaper discusses the growing demand for supply chain management and compliance standards needed for managing cell and gene materials. $CYRX
Read The Whitepaper: https://cyrx.co/4cFFaQ4
